89bio, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 24.6 million compared to USD 26.29 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 1.3 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.81 USD | -1.14% | -4.93% | -29.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.19% | 777M | |
+14.67% | 118B | |
+12.95% | 106B | |
-3.12% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-17.34% | 15.56B | |
+4.43% | 13.63B | |
+27.96% | 12.27B |
- Stock Market
- Equities
- ETNB Stock
- News 89bio, Inc.
- 89bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022